title: Corrections needed to 2016 ESC and AHA guidelines on heart failure.
authors.affiliation: Cardiology Unit, Department of Medicine, Solna Karolinska Institutet, Stockholm 171 76, Sweden. Electronic address: lars.ryden@ki.se.
authors.forename: Lars
authors.initials: L
authors.lastname: Rydén
authors.affiliation: Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
authors.forename: Frans
authors.initials: F
authors.lastname: Van de Werf
authors.affiliation: Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
authors.affiliation: Munich Diabetes Research Group e. V., Helmholtz Centre, Neuherberg, Germany.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.affiliation: Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Peterson
authors.affiliation: Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK.
authors.forename: Rury R
authors.initials: RR
authors.lastname: Holman
mesh_terms: D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D017408:Guidelines as Topic; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D054795:Incretins / Q000097:blood
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins